Chosen Names and Pronouns

Evidence Note

What is the question?

Does correctly using a transgender or gender-diverse patient’s chosen name and pronouns produce clinically meaningful benefit — enough to treat it as a component of care rather than mere courtesy? And where the supporting evidence is borrowed from an adjacent field or a different age group, how far can it legitimately be carried into the adult trans clinical encounter?

What does the evidence say?

Start with what is best established, even though it is not trans-specific. The quality of the clinical relationship — the bond between patient and clinician, and their agreement on the goals and tasks of care — is one of the most replicated predictors of outcome in psychotherapy. That literature is large and consistent, but it was built in largely cisgender or unspecified populations, so it speaks to clinical relationships in general rather than to names, or to trans patients, in particular.

Bridging toward this population, minority stress theory — developed for sexual-minority people, then adapted specifically for transgender clinical work — treats being misnamed or misgendered as an instance of “nonaffirmation,” a recognised proximal stressor with a theorised path to distress. It offers a coherent, trans-specific mechanism for how a name could matter.

The population-specific findings line up with that mechanism. In transgender adults, being misgendered is associated with more negative emotion, a reduced sense of authenticity, and greater felt stigma. In transgender youth, being able to use a chosen name across more settings — home, school, work, with friends — is associated with lower depression, suicidal ideation, and suicidal behaviour. And at the level of the clinic, mistreatment is common: a large survey of trans adults found a third reported a negative, gender-related experience with a provider in the past year, and nearly a quarter had avoided needed care for fear of being mistreated — avoidance that itself tracks with worse general and mental health.

How strong is the evidence?

It is convergent but mostly indirect or observational, which places it at moderate, not high, certainty. The strongest, most replicated strand — relationship quality and outcome — is general and correlational. The mechanism, minority stress and nonaffirmation, is trans-specific and well-developed, but it is a model rather than outcome proof. The most direct adult data on misgendering come from cross-sectional online convenience samples, which show association, not causation. The most-cited study tying chosen-name use to better mental health is in adolescents rather than adults, and is also cross-sectional. No trial has isolated correct name and pronoun use in an adult trans clinical encounter and measured a downstream health outcome.

The single best-evidenced and most actionable element is not a precise effect size but a direction: across every strand, getting names and gender right travels with better experience and engagement, and getting them wrong travels with avoidance and worse health. The cost of acting on that direction is close to nothing.

Where are the uncertainties?

The central limitation is population mismatch. The relationship-quality evidence is borrowed from general, largely cisgender care; the foundational minority-stress evidence was built in sexual-minority rather than transgender populations; and the strongest name-specific study is paediatric. Each step toward “use the patient’s name in clinic and outcomes improve” crosses at least one of those gaps. Because the directly relevant studies are observational, they also cannot rule out that supportive environments independently drive both name use and better mental health. And the operational specifics — whether asking at first contact matters, whether a prompt correction offsets an error, whether record-system supports help — remain untested.

When the evidence is consistent, the mechanism coherent, and the risk close to nil, the missing trial is a reason for humility about size — not a reason to wait.

Incomplete certainty about magnitude is not the same as doubt about direction.

What does this mean for practice?

Although certainty is incomplete, a number of practical conclusions can still be drawn.

The clearest is also the lowest-risk: ask transgender and gender-diverse patients what name and pronouns they use, and then use them. The evidence for benefit is moderate, but the cost is negligible, the risk is effectively nil, and every available strand points the same way. Few practices in healthcare combine that little downside with that consistent a direction of evidence.

Beyond the individual clinician, the same evidence supports treating correct name and pronoun use as part of a respectful encounter that reduces fear-driven avoidance of care — which means reception, records, and intake systems matter alongside the consultation itself. What the evidence does not yet support is a precise claim about how much benefit follows, or a single best protocol for delivering it.

So the honest framing is modest and firm at once: correct name and pronoun use is a well-aligned, low-risk practice with consistent supporting evidence — not a proven-magnitude treatment. The principle that names matter is better evidenced than any particular method for honouring them.